Abstract: The influence of three newly developed bispyridinium antinicotinic compounds (the non-oximes MB408, MB442 and MB444) on the therapeutic efficacy of a standard antidotal treatment (atropine in combination with an oxime) of acute poisoning by the organophosphorus nerve agents tabun and soman was studied in mice. The therapeutic efficacy of atropine in combination with an oxime with or without one of the bispyridinium non-oximes was evaluated by determination of the LD 50 values of the nerve agents and measurement of the survival time after supralethal poisoning. Addition of all the tested non-oximes increased significantly the therapeutic efficacy of atropine in combination with an oxime against tabun poisoning. They also positively influenced the number of surviving mice 6 hr after supralethal poisoning with tabun. However, they were only slightly effective for the treatment of soman poisoning. The benefit of the tested bispyridinium non-oximes was dose-dependent. To conclude, the addition of bispyridinium non-oximes to the standard antidotal treatment of acute poisoning with tabun was beneficial regardless of the chosen non-oxime, but only slightly beneficial in the case of soman poisoning.
Highly toxic organophosphorus nerve agents exert their acute toxic effects via irreversible inhibition of the enzyme acetylcholinesterase (AChE, EC 3.1.1.7) in the central and peripheral nervous system by phosphylation (phosphorylation or phosphonylation) of its active-site serine hydroxyl group. Inhibition of AChE after exposure to nerve agents leads to the accumulation of the neurotransmitter acetylcholine in the synaptic cleft and subsequent overstimulation of muscarinic (mAChRs) and nicotinic acetylcholine receptors (nAChRs) that results in signs and symptoms of acute cholinergic crisis. These include fasciculations, muscle paralysis, lachrymation, miosis, salivation, respiratory failure, seizures and coma [1] . Death occurs due to central and peripheral respiratory failure resulting from bronchospasm, excessive bronchial secretion, paralysis of respiratory muscles and depression of brain respiratory centres [2, 3] .
Medical countermeasures to nerve agent poisoning usually comprise a combined administration of an anticholinergic drug (preferably atropine) to block the overstimulation of cholinergic receptors by accumulated acetylcholine (ACh) at muscarinic receptor sites, an oxime (e.g. HI-6 or trimedoxime, fig. 1A ) to repair the biochemical lesion by dephosphylation of AChE and restore its activity, and a benzodiazepine (usually diazepam) to control seizures and convulsions [4, 5] . Although antidotes against nerve agents have been developed based on knowledge of the aforementioned basic mechanism of acute toxicity of nerve agents, their efficacy is limited mainly by the reactivating efficacy of commonly used oximes, especially in the case of acute poisoning with tabun, soman and cyclosarin [6] [7] [8] [9] .
The effectiveness of oxime treatment depends on many factors, especially the chemical structure of the nerve agent and the rate of ageing of the enzyme-inhibitor complex. Tabun (O-ethyl N,N-dimethylphosphoramidocyanidate) differs in chemical structure from other nerve agents and by the fact that its deleterious effects are difficult to antagonize due to the resistance of the AChE-tabun complex to nucleophilic reactivation by oximes [10, 11] . The deleterious effects of soman (pinacolyl methylphosphonofluoridate) are also difficult to counteract, due to rapid ageing of soman-inhibited AChE. Spontaneous dealkylation of soman bound to the active site of AChE makes the nucleophilic attack of oximes almost impossible [7, 12] . Other factors that influence oxime therapy include the inhibition potency of nerve agents and their toxicokinetics, the reactivating potency of oximes and their pharmacokinetics, the correct dosing and the timing of therapy administration [13, 14] .
Because of the limited efficacy of oximes, the antidotal treatment of acute poisoning by tabun and soman still remains a serious challenge and the development of new and more effective antidotes is still required [15] . One possible approach to overcome the limitations of antidotal treatment is to incorporate a nAChR antagonist to oppose the effects of nerve agents in target organs mediated by nAChRs, thus reducing the reliance on AChE reactivation by oximes [16] .
The nAChR is one of the most pharmacologically important targets for new therapeutic approaches to counter nerve agent-induced acute toxicity [17, 18] . Although atropine effectively counteracts the toxic effects of nerve agents at mAChRs, it has no therapeutic effect at nAChRs [19] . Thus, functional recovery of nAChR-mediated synaptic transmission is only indirectly achieved by the often limited reactivation of inhibited AChE mediated by the oxime component of the therapy. This recovery is especially important in the case of tabun or soman exposure because of very limited reactivation of soman-or tabuninhibited AChE.
Several years ago, MB327, a bispyridinium compound without an oxime group, showed a marked therapeutic effect in nerve agent-poisoned guinea pigs that is believed to be due to its non-competitive inhibition of nAChRs [16, 20] . However, its ability to increase the efficacy of the standard antidotal treatment of acute poisoning with nerve agents in mice was not as high as expected [21] . Therefore, the quest for more efficacious bispyridinium ion channel blockers able to increase markedly the efficacy of current antidotal treatment of nerve agents -regardless of their chemical structure -continues. Recently, three novel bispyridinium non-oximes (MB408, MB444 and MB442; fig. 1B ) differing by the structure of the linker connecting the two pyridinium rings have been developed and synthesized to improve the efficacy of antidotal treatment of acute nerve agent poisoning. The aim of this study was to evaluate the potential benefit of these compounds for the antidotal treatment of acute poisoning by tabun and soman in mice.
Material and Methods
Animals. Male NMRI mice weighing 25-30 g were purchased from VELAZ (Prague, Czech Republic). They were housed in propylene, solid bottom cages in climate-and access-controlled rooms (22 AE 2°C and 50 AE 10% relative humidity). The day/night cycle was 12/12 hr. Food and tap water were available ad libitum. The mice were divided into groups of eight animals. Their handling was performed under the supervision of the Ethics Committee of the Faculty of Military Health Sciences in Hradec Kralove (Czech Republic).
Chemicals. Tabun and soman were obtained from the Military Technical Institute in Brno (Czech Republic) in 90-95% purity (by acidimetric titration). Stock solutions of the nerve agents (1 mg/ml) were prepared in propylene glycol 3 days before starting the experiments. These solutions were diluted with saline immediately before administration. Oximes (HI-6, trimedoxime) were synthesized in the Department of Toxicology and Military Pharmacy of the Faculty of Military Health Sciences in Hradec Kralove (Czech Republic) [22] . Their purity was analysed using an HPLC technique with UV detection (310 nm) and exceeded 96% [23] . The bispyridinium non-oximes MB408, MB444 and MB442 were synthesized at Dstl Porton Down, Salisbury (United Kingdom) as described below. Other chemicals of analytical grade were obtained commercially and used without further purification. All substances were administered by intramuscular (i.m.) injection at a volume of 10 ml/kg body-weight (b.w.).
Synthesis. The synthesis of the bispyridinium non-oximes by bisquaternization of a greater than two times molar excess of a pyridine with a,x-diiodoalkanes has been discussed in detail [24] and used previously to prepare MB327 [20, 21] . Bis-quaternization rarely proceeds at room temperature at a rate that is synthetically useful. Prolonged heating is required in a suitably inert solvent, whose boiling point determines the temperature the reaction mixture can The bispyridinium oximes HI-6 and trimedoxime. The latter has a propylene linker and was one of the prototypes for the design of the bispyridinium non-oximes. The oxime groups when present confer an ability to reactivate AChE inhibited by certain organophosphorus nerve agents, by nucleophilic attack on the serine-bound nerve agent residue, resulting in its release and liberation of uninhibited AChE, which can then function normally. (B) The bispyridinium antinicotinic compound (non-oxime) series with the simplest core structure (no additional decoration of the pyridinium rings with functional groups). The ones selected for synthesis and biological evaluation herein contained propylene (C3), butylene (C4) or pentylene (C5) linkers. Their structure is compared to that of MB327 which contains tert-butyl groups in the 4-position of the pyridinium rings, and the same propylene linker as trimedoxime dibromide and the non-oxime MB408. The absence of oxime groups in the MB compounds discounts the possibility that their therapeutic effect is linked to reactivation of nerve agent-inhibited AChE. The prefix MB stands for 'Mike Bird' who synthesized the bispyridinium non-oxime series at Dstl Porton Down (United Kingdom). The number after the MB prefix signifies the sequential compound number in his laboratory notebook denoting the first preparation of each compound.
achieve under reflux conditions, which are preferable. The rate of bisquaternization therefore will depend upon the concentration of the starting reagents in the solvent, the temperature attainable upon reflux of the reaction mixture and the polarity of the solvent (polar solvents generally accelerate the reaction compared to non-polar ones). Because of these factors, it is often necessary to experiment considerably to find procedures able to furnish high yields of the desired products reliably. Toluene (bp 111°C), acetonitrile (bp 81°C) and nitromethane (bp 101°C) can be used as solvents, and their employment to prepare in high yields, and in greater than 99% purity (an HPLC method [25] ), the target bispyridinium non-oximes ( Fig. 2 ) are now described. These methods have been repeated successfullyin some cases several times. Thin-layer chromatography (TLC) was performed on MK6F silica gel 60-A plates (Whatman, USA) with detection by iodine vapour. Nuclear magnetic resonance (NMR) experiments were collected at 9.4T using a Bruker Avance III spectrometer equipped with a 5-mm BBFO+ probehead. Anhydrous solvents were used throughout.
1,1
0 -(Propane-1,3-diyl)bispyridinium diiodide MB408. To a 250-ml two-necked round-bottomed flask were added pyridine (5.93 g, 75 mmol), toluene (100 ml) and a magnetic stirrer bar. The centre neck was fitted with a double-surface condenser topped with a guard tube containing anhydrous calcium chloride. The side neck was fitted with a pressure-equalizing dropping funnel from which a solution of 1,3-diiodopropane (7.40 g, 25 mmol) in toluene (25 ml) was added dropwise with stirring over 30 min. TLC analysis, eluting the plate with 1:2 v/v hexane-acetone, showed only starting materials. The mixture was heated under reflux and a significant quantity of precipitate was formed. The progress of reaction was monitored by TLC. After 26 hr 45 min., TLC revealed the complete disappearance of 1,3-diiodopropane, the presence of the excess of pyridine, and a faint baseline spot corresponding to the desired product. The fine yellow precipitate was filtered off and dried under vacuum to constant weight (11.00 g). Its crystallization from hot ethanol provided MB408 as yellow crystals (10.33 g, 91% 
0 -(Butane-1,4-diyl)bispyridinium diiodide MB444. The same apparatus set-up described above was used for this preparation and those that follow. A solution of 1,4-diiodobutane (7.75 g, 25 mmol) in acetonitrile (25 ml) was added to a stirred solution of pyridine (5.93 g, 75 mmol) in acetonitrile (100 ml). The whole was heated under reflux for 20 hr 15 min. At this point, TLC analysis, using 1:2 v/v hexane-acetone as eluent, indicated that the reaction had proceeded to completion (no 1,4-diiodobutane spot, a faint pyridine spot, a very faint spot at retention factor (R f ) 0.1 and a dark baseline product spot). The white precipitate was filtered off and dried under vacuum to constant weight (10.80 g). Its crystallization from hot ethanol gave MB444 as fine white needles (10.12 g, 86% 
0 -(Pentane-1,5-diyl)bispyridinium diiodide MB442 (acetonitrile method, smaller scale). A solution of 1,5-diiodopentane (8.10 g, 25 mmol) in acetonitrile (25 ml) was added to a stirred solution of pyridine (5.93 g, 75 mmol) in acetonitrile (100 ml). The whole was heated under reflux and assumed a yellow colour upon heating. After refluxing for 9 hr 45 min., TLC analysis eluting the plate with 1:2 v/v hexane-acetone, showed no 1,5-diiodopentane spot, a faint pyridine spot (R f = 0.55), a very faint spot (R f = 0.10) and two other spots (R f = 0.05 and 0.00 (baseline)). Heating under reflux was continued to a total duration of 27 hr 30 min. for the experiment, after which TLC analysis confirmed no change to the above picture of products in the reaction mixture. The solvent was removed by rotary evaporation to leave a sticky solid which was dried to constant weight using a vacuum pump. Crystallization of the solid using hot ethanol yielded MB442 as creamy white crystals (10.63 g, 88% In vivo experiments. Before starting the evaluation of the therapeutic efficacy of antidotes, the acute toxicity of all newly developed bispyridinium non-oximes was determined in mice. LD 50 values and 95% confidence limits were determined using probit-logarithmical analysis of death occurring within 24 hr after i.m. administration of each compound at five different doses, with eight animals per dose [26] LD 50 values of all other antidotes (atropine, oximes) tested and their 95% confidence limits were reproduced from previous publications [21, 27] .
The ability of different therapeutic combinations to prevent nerve agent-induced lethal effects in mice was assessed as follows. The LD 50 values of the nerve agents and their 95% confidence limits in nerve agent-poisoned mice were assessed using probit-logarithmical analysis of death occurring within 24 hr after i.m. administration of nerve agent at five different doses, with eight mice per dose [26] . Then, nerve agent-poisoned mice were treated i.m. with atropine in combination with an oxime, with or without one of the MB compounds. The saline solutions of all antidotes studied were prepared immediately before their administration. For each nerve agent, one of the most effective oximes versus the specific nerve agent was chosen for the evaluation of the benefit of bispyridinium non-oximes (trimedoxime for tabun and HI-6 for soman) [2, 6, 8, 13] . The oximes were administered at equitoxic doses corresponding to 10% of their respective LD 50 , while MB compounds were administered at two different doses equating to 10 and 20% of their respective LD 50 . Equitoxic doses were used to be sure that sufficiently safe doses of all antidotes studied with respect to their different toxicity were administered. Based on previous studies, atropine was administered at a dose of 10 mg/kg, corresponding approximately to 2% of its LD 50 value [27] . All antidotes were administered at 1 min. after an i.m. challenge of nerve agent. The LD 50 values of nerve agents and their 95% confidence limits in nerve agent-poisoned mice treated with antidotes were assessed by the same method as the initial toxicity of the therapies [26] . The efficacy of tested antidotes was expressed as a protective ratio A (LD 50 value of nerve agent in protected mice/LD 50 value of nerve agent in unprotected mice) and as a protective ratio B (LD 50 value of nerve agent in mice treated with atropine and oxime with MB compound/LD 50 value of nerve agent in mice treated with atropine and oxime without MB compound). Statistical significance was determined by the use of a one-way ANOVA test with Scheffe's post hoc test, and differences were considered significant when p < 0.05 [26] .
To evaluate the influence of all bispyridinium non-oximes on the time to death of nerve agent-poisoned mice, the animals were poisoned intramuscularly with supralethal doses of tabun (2 9 LD 50 ) or soman (3 9 LD 50 ); one minute later, an intramuscular injection of therapy was administered, containing atropine and an oxime with or without the MB compound. The animals were monitored for signs of poisoning up to 6 hr, and times of death were noted.
Results
The acute i.m. toxicity of the tested antidotes in mice is summarized in Table 1 . The acute toxicity of the bispyridinium nonoxime MB408, having a C3 linker, was relatively low and comparable with the acute toxicity of the oxime HI-6, while the acute toxicity of the other bispyridinium non-oximes MB444 and MB442, having C4 and C5 linkers, respectively, was markedly higher than that of MB408 and roughly comparable to that of trimedoxime. Thus, the acute toxicity of these MB compounds showed a dependence on the length of the alkane linker separating the pyridinium units. As the linker extended from C3 to C5, the toxicity increased progressively. Animals administered acutely toxic doses of MB compounds showed various signs of poisoning, including tremor followed by loss of movement, flaccid paralysis and respiratory difficulties. Deaths occurred within 30 min. The oxime HI-6 is significantly less toxic than trimedoxime and was used at higher doses in the efficacy studies.
A comparison of the therapeutic efficacy of the drug combinations tested is summarized in tables 2 and 3. Tabun-or soman-poisoned mice showed a wide spectrum of clinical signs of poisoning including muscarinic (salivation) and nicotinic (tonic-clonic convulsions) signs within a few minutes, regardless of the composition of antidotal treatment. Deaths occurred within 20-50 min. after poisoning with nerve agents, regardless of the type of nerve agent and antidotal treatment. The standard antidotal treatment of acute poisoning with tabun (atropine + trimedoxime) increased the LD 50 value 1.7 times (Table 2) . When this standard antidotal treatment was combined with MB408 (C3 linker), the therapeutic efficacy of the combined treatment was consistently higher when compared to the treatment without MB408. The LD 50 value of tabun was increased 1.28 times or 1.55 times (protective ratio B) depending on the dose of MB408. Thus, the benefit of MB408 was dose-dependent. While the treatment containing the lower dose of MB408 increased the LD 50 value of tabun 2.2 times, that with the higher dose of MB408 increased the LD 50 value 2.7 times. The differences between the ability of standard treatment, and the same treatment in combination with MB408, to decrease the acute toxicity of tabun were statistically significant (p < 0.05).
MB444 (C4 linker) was able to increase significantly the LD 50 value of tabun at the higher dose only, compared to treatment without MB444 (p < 0.05) and it increased 2.1 times compared to no treatment (Table 2) . When the standard antidotal treatment was combined with the higher dose of MB444, the therapeutic efficacy of the combined treatment was higher when compared to the treatment without MB444. The LD 50 value of tabun was increased 1.21 times (protective ratio B). The differences between the ability of standard treatment and the same treatment in combination with the higher dose of MB444 to decrease the acute toxicity of tabun were statistically significant (p < 0.05) ( Table 2) .
Both doses of MB442 (C5 linker) were able to significantly increase the LD 50 value of tabun: it was increased 2.1 times when the lower dose of MB442 was used, and 2.3 times with the higher dose of MB442 (p < 0.05). When the standard antidotal treatment was combined with MB442 (C5 linker), the therapeutic efficacy of the combined treatment was consistently higher when compared to the treatment without MB442. The LD 50 value of tabun was increased 1.20 times or 1.34 times (protective ratio B) depending on the dose of MB442. Thus, the benefit of MB442 was also dose-dependent. The differences between the ability of standard treatment and the same treatment in combination with MB442 to decrease the acute toxicity of tabun were statistically significant (p < 0.05). The standard antidotal treatment of acute poisoning with soman (atropine + HI-6) increased the LD 50 value 2.3 times (Table 3) . When this standard antidotal treatment was combined with MB408 (C3), MB444 (C4) or MB442 (C5), the therapeutic efficacy of the combined treatment was only slightly higher compared to the treatment without MB compounds (see protective ratio B in Table 3 ). The benefit of all bispyridinium non-oximes was dose-dependent; however, the differences between the higher and lower doses of all MB compounds were very small. The higher dose of MB442 and MB444 was able to increase the LD 50 value 2.6 times. In addition, the differences between the ability of standard treatment and the same treatment in combination with MB compound to decrease the acute toxicity of soman were not statistically significant.
An evaluation of the influence of all bispyridinium non-oximes on the time to death of animals poisoned with supralethal doses of tabun or soman is summarized in tables 4 and 5. The ability to prolong the time to death of animals poisoned with supralethal doses of tabun or soman roughly corresponds to their ability to decrease acute toxicity of both nerve agents. While both doses of MB408 and higher doses of MB442 and MB444 were able to markedly decrease the number of animals dying within 1 and 6 hr after poisoning with tabun (Table 4) , only the higher dose of MB408 and both doses of MB444 were able to markedly decrease the number of animals dying within 6 hr after poisoning with soman (Table 5 ).
Discussion
The acute poisoning with nerve agents is usually treated by the combination of anticholinergic drug (usually atropine), oxime (usually pralidoxime or obidoxime) and anticonvulsive drug (usually diazepam) [2] . However, the efficacy of this standard antidotal treatment is somewhat limited. Atropine is able to counteract the overstimulation of mAChRs but not the overstimulation of nAChRs, and the ability of oximes to reactivate nerve agent-inhibited AChE depends on many factors, especially the chemical structure of the bound nerve agent residue and the rate of ageing of the enzyme-inhibitor complex. A particular oxime may be effective against a specific nerve agent and ineffective against others [14, 20] . The benefit of oximes involves not only their limited ability to reactivate nerve agent-inhibited AChE but also other effects, including direct effects on ion channels and receptors [28] [29] [30] and, potentially, a direct reaction of the oximes with nerve agents [31] . Among them, the direct block exerted by certain bispyridinium oximes on nAChR ion channels, which correlates with recovery of neuromuscular function in soman-poisoned nervemuscle preparations, was demonstrated [32] . Based on this finding, bispyridinium non-oximes were developed to optimize this aspect of bispyridinium action to improve recovery of neuromuscular function by a presumed non-competitive mechanism of action [16, 33] . It has also been suggested that these bispyridinium non-oximes possibly interact with nAChR subtypes as positive allosteric modulators [34] . The addition of the bispyridinium non-oxime MB327 to the antidotal treatment of acute nerve agent poisoning is consistently beneficial [20, 21, 25] . Here, we have examined the related bispyridinium non-oximes MB408 (C3), MB444 (C4) and MB442 (C5 linker), which have been shown to antagonize both muscle and neuronal nicotinic receptors [33] . When these MB nicotinic antagonists were added to the standard antidotal treatment of acute poisoning by tabun, its acute toxicity was significantly decreased compared to the standard antidotal treatment without MB compounds. While MB408 (C3) and MB442 (C5) were able to decrease significantly the acute toxicity of tabun at both doses, MB444 (C4) was markedly effective at the higher dose only. This effect of MB compounds roughly corresponds to their potency to prolong the time to death of animals poisoned with a supralethal dose of tabun. In the case of soman, both MB444 (C4) and MB442 (C5) also decreased the acute toxicity of soman compared to standard antidotal treatment without an antinicotinic antagonist added and prolonged the time to death of animals poisoned with a supralethal dose of soman, but their benefit was not significant, and it was lower when compared to tabun poisoning.
Taken together, the present and previously published data provide evidence for additional efficacy resulting from the inclusion of the antinicotinic compounds in standard antidotal therapy. This type of antidotal treatment attempts to address a spectrum of acute cholinergic signs and symptoms caused by overstimulation of both muscarinic and nicotinic AChRs. As MB compounds will poorly penetrate the blood-brain barrier because of their charged structure, their effects will be predominantly peripheral (like those of many of the oximes, e.g. HI-6 or trimedoxime). It was shown that certain bispyridinium non-oximes are able to improve the function of nerve agentpoisoned neuromuscular preparations in vitro [16, 35] which correlates with their ability to block nicotinic ion channels [32] . In addition, bispyridinium non-oximes as well as bispyridinium oximes also interact with a number of other targets (especially mAChRs) that might provide protection against signs and symptoms of an acute cholinergic crisis [18, 36, 37] . However, it is not clear whether their antimuscarinic action will provide any additional benefit over that already provided by the doses of atropine already used [24] .
In conclusion, these results for MB408, MB442 and MB444 confirm that antinicotinic compounds may be considered to be promising for inclusion in the currently used antidotal treatment of nerve agent poisoning. The benefit of the studied MB compounds for the therapeutic efficacy of standard antidotal treatment against both nerve agents studied was clearly demonstrated, although at the doses used they only provided significant protection in the case of tabun poisoning. Due to their presumed mechanism of action in antagonizing the effects of excess ACh on muscarinic and nicotinic postsynaptic receptors, the combination of MB compound, atropine and oxime should be expected to counteract the acute toxicity of all nerve agents regardless of their chemical structure. However, the benefit of the bispyridinium non-oximes may vary according to the nerve agent and must be evaluated carefully. 
